INTRODUCTION

Blood transfusion is performed for improvement in oxygen delivery (DO₂) at tissue level and to improve blood volume. Despite this supposed physiological benefit, paradoxically, both anaemia and transfusion are independently associated with organ injury and increased morbidity. Traditionally, the decision to transfuse red blood cells (RBCs) was based upon the ‘10/30 rule’; to maintain blood haemoglobin (Hb) concentration above 10 g/dL and a haematocrit above 30%. However, reports of several series of patients who refuse blood transfusions demonstrate that a variety of major operations are tolerated without apparent major morbidity or mortality. The Agency for Healthcare Research and Quality reported that in 2007, blood transfusions were given in one in every ten hospital admissions in which a procedure was performed leading to 140% increase from 1997 in the USA.

This narrative review focuses on RBC transfusion with respect to physiological rationale, risks, complications and the appropriate transfusion trigger for various conditions.

RATIONALE FOR TRANSFUSION

The efficacy of transfused RBC's may be related to three mechanisms, circulatory (volume) effects, rheological effects (blood flow/viscosity) and effects on oxygen transportation.

Circulatory volume expansion of RBC transfusions is immediate but is not usually recommended except for cases of trauma or surgical cases with massive blood loss as there is a risk of transfusion-associated circulatory overload.

Rheological effect on blood viscosity is an important factor for maintaining microvascular circulation. High haematocrit will cause an increase in viscosity and may compromise the microcirculation.

Oxygen (O₂) delivery rises with the rise in Hb (approximately 1 g/dL per unit of RBC transfused)
and is often viewed as the main reason for giving blood.

Oxygen is carried in the blood from the lungs to the other organs predominantly bound to the haemoglobin group of Hb within the RBC. Negligible amount of oxygen is carried in plasma in a dissolved form. The sum of these two components makes up the total arterial oxygen content (CaO$_2$).

$$\text{CaO}_2 = (\text{Hb} \times 1.34 \times \text{SaO}_2) + (0.003 \times \text{PaO}_2)$$

(SaO$_2$ is the Hb oxygen saturation, [Hb] is the blood Hb concentration, and PaO$_2$ is the partial pressure of oxygen in arterial blood).

One gram of Hb carries 1.34 ml of oxygen as oxyhaemoglobin, and a factor of 0.003 determines the amount of oxygen carried dissolved in plasma.

Under normal physiological conditions, the amount of oxygen dissolved in plasma is negligible compared with the amount of oxygen that is bound to Hb.

The key issue in determining tissue oxygenation is the balance between the global DO$_2$ oxygen delivery (DO$_2$) and the global oxygen consumption (VO$_2$).

Oxygen delivery is a function of cardiac output (CO) and the arterial oxygen content (CaO$_2$)

$$\text{DO}_2 = \text{CO} \times \text{CaO}_2$$

VO$_2$ is global oxygen consumption and will depend on metabolic rate as well as ability of tissues to utilize oxygen.

$$\text{VO}_2 = \text{CO} \times (\text{CaO}_2 - \text{CvO}_2)$$

CvO$_2$ – total venous oxygen content.

Oxygen extraction ratio is the ratio of VO$_2$/DO$_2$ and is normally around 20-30%, allowing a significant safety margin. The rate of delivery normally exceeds consumption by a factor of four. Thus, if intravascular volume is maintained while bleeding and cardiovascular status is not impaired, DO$_2$ will remain adequate until the haematocrit falls below 10%. This is due to a compensatory increase in cardiac output, the rightward shift of the oxygen-Hb dissociation curve and increased oxygen extraction [Figure 1].

As a result of this sufficient reserve, initially despite a decrease in DO$_2$, VO$_2$ is unaffected and remains stable (this is described as DO$_2$-independence). However, as the DO$_2$ decreases and approaches VO$_2$, a critical DO$_2$ point (DO$_2$ CRIT) is reached when the DO$_2$ is no longer sufficient to keep up with the VO$_2$, resulting in a drop in VO$_2$ and development of tissue ischemia.

This DO$_2$-VO$_2$ relationship gives us a rationale for using RBC transfusions in order to improve DO$_2$ to tissues, but this may not always be so. Using central venous oxygen saturation (SvO$_2$), a DO$_2$/VO$_2$ based target for RBC transfusion in septic patients has not shown benefit in two recent trials.[5,6]

**RATIONALE FOR AVOIDING TRANSFUSION**

Observational studies have shown an association between anaemia and increased mortality, however, there is no clear data suggesting whether correction of anaemia will improve mortality.[2] RBC transfusions result in an increase in Hb, but an immediate increase in DO$_2$ is not seen. The reasons for this transient inability of transfused RBC’s to effectively deliver oxygen to the end organs may be explained by the effects of blood storage[7] [Table 1].

Also, most patients with acute anaemia will increase tissue DO$_2$ by increasing cardiac output over a range of Hb concentrations. Other mechanisms for adaptation to anaemia include redistribution of blood flow to essential circulatory beds, increased coronary blood flow, increased oxygen extraction and increase in RBC 2,3-diphosphoglycerate.

The other rationale for avoiding RBC transfusions is due to the risks and complications of transfusion that are enlisted in the Table 2 below.[8]
The anaemia and blood transfusion in critical care (ABC) study, a large epidemiologic survey of 3534 patients in 146 western European intensive care units (ICUs) showed increased mortality rates (ICU and hospital) in transfused patients.\[9\]

In view of this data and lack of clarity of appropriate transfusion trigger, a single pre-specified transfusion criterion is not justified as an indication for RBC transfusion.\[10\]

**RED BLOOD CELL TRANSFUSION TRIGGERS**

Different transfusion thresholds have been studied in different patient populations.\[11-18\] An appropriate transfusion trigger is defined as one which balances the benefit of treating anaemia and the risk of unnecessary transfusions.

Generally accepted terminologies include ‘liberal strategy’ with transfusion threshold Hb of 9-10 g/dL and ‘restrictive strategy’ with transfusion Hb thresholds of 7-8 g/dL.

Large randomized controlled trials (RCT’s) studying liberal versus restrictive strategies for transfusion are relatively few and include select group of patients like critically ill patients, cardiac surgical patients, and elderly orthopaedic patients with cardiovascular risk.

**EVIDENCE IN CRITICALLY ILL PATIENTS**

Transfusion requirements in critical care (TRICC)\[11\] trial was a multicentre randomised controlled clinical trial of transfusion requirements in critically ill patients. It enrolled 838 critically ill patients with euvoemia who after initial treatment had Hb concentrations of < 9.0 g/dL within 72 h after admission to the ICU. 418 patients were assigned to a restrictive strategy of transfusion, in which red cells were transfused if the Hb concentration dropped below 7.0 g/dL and Hb concentrations were maintained at 7.0-9.0 g/dL and 420 patients were assigned to a liberal strategy, in which transfusions were given when the Hb concentration fell below 10.0 g/dL and Hb concentrations were maintained at 10.0-12.0 g/dL. No difference in overall 30 days mortality in the two groups was seen but the 30 days mortality rates were significantly lower with the restrictive transfusion strategy in patients who were less acutely ill with an Acute Physiology and Chronic Health Evaluation II score of <20 and in patients who were <55 years of age. The authors concluded that a restrictive strategy of red-cell transfusion is at least as effective as and possibly superior to a liberal transfusion strategy in critically ill patients, with the possible exception of patients with acute myocardial infarction (MI) and unstable angina.\[11\]

A recent RCT\[12\] on ‘lower versus higher Hb threshold for transfusion requirements in septic shock’ (TRISS) patients did not find any difference in mortality at 90 days, rates of ischemic events and use of life supports.

**EVIDENCE FOR ELDERLY ORTHOPEDIC PATIENTS WITH CARDIOVASCULAR RISKS**

Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS) trial\[13\] by Carson et al. looked at elderly patients with a history of risk factors for cardiovascular disease who were undergoing hip surgery. It randomised 2016 elderly patients to either restrictive or liberal transfusion strategies. The liberal transfusion group received immediate transfusion of one unit of packed

| Table 1: Storage lesions |
|--------------------------|
| **Biochemical changes**  |
| Increased levels of potassium, sodium, lactate, glucose, increased cytokines (IL-1β, IL-6, IL-8, MCP1) |
| Decrease in pH, ATP and 2,3-DPG depletion |
| **Altered functionality** |
| Increased RBC rigidity, reduced deformability |
| Enhanced adhesion to endothelial cells |
| Altered affinity to oxygen |
| Reduced ability to bind and deliver NO |
| **Organ injury**          |
| Inflammation              |
| Coagulopathy              |
| Impaired RBC-induced vasodilation |
| Impaired oxygen delivery   |

RBC – Red blood cell; IL – Interleukin; MCP – Monocyte chemoattractant protein; 2,3-DPG – 2,3-diphosphoglycerate; ATP – Adenosine triphosphate; NO – Not other

| Table 2: Risks and complications of RBC transfusions |
|------------------------------------------------------|
| Infection with transfusion-transmitted pathogens (e.g., viruses, bacteria, and parasites) |
| Allergic and immune transfusion reactions (e.g., ‘immunologic transfusion reactions’ and ‘Transfusion-associated immune and non-immune-mediated haemolysis’ and ‘TRALI’) |
| Volume overload (TACO) |
| Massive transfusion leading to hyperkalaemia |
| Hypocalcaemia resulting from citrate toxicity |
| Hypothermia |
| Transfusion-mediated immunosuppression and increased risk of post-operative bacterial infection |
| Cancer recurrence in patients with colorectal cancer |

TRALI – Transfusion-related acute lung injury; TACO – Transfusion-associated circulatory overload; RBC – Red blood cell
RBCs plus subsequent transfusions to raise the Hb level to > 10 g/dL whenever it fell below this level. The restrictive transfusion group received single unit transfusions only if they developed symptoms of anaemia (defined as chest pain, orthostatic hypotension, tachycardia unresponsive to fluid resuscitation, or congestive heart failure) or, in the absence of symptoms, when the Hb level fell below 8 g/dL. The study concluded that liberal transfusion strategy was not associated with improved outcomes (mortality, ability to walk independently, acute coronary syndrome and other complications) compared with a restrictive transfusion strategy. The restrictive transfusion strategy was however associated with a non-statistically significant higher risk of MI.

**EVIDENCE FOR CARDIAC SURGICAL PATIENTS**

Trials suggest that a restrictive transfusion strategy with an Hb threshold of 8 g/dL appears to be safe in patients undergoing cardiac surgery with cardiopulmonary bypass. The first trial by Bracey et al.[14] randomly assigned 428 consecutive patients undergoing coronary artery bypass grafting to the post-operative transfusion either at a Hb < 8 g/dL, or at an institutional guideline of Hb < 9 g/dL. There was no difference in morbidity, mortality, or self-assessment for fatigue or anaemia between the two groups. Post-operative transfusion rates were significantly lower for the group with the lower transfusion threshold (0.9 vs. 1.4 RBC units/patient), amounting to savings of 500 RBC units per 1000 CABG. The second trial, ‘transfusion requirements after cardiac surgery’ TRACS[15] randomized 502 consecutive patients who underwent coronary artery bypass grafting to a liberal or restrictive transfusion strategy (to maintain haematocrit at 30% or 24%) throughout surgery and the post-operative period. The primary outcome was a composite endpoint of 30 days all-cause mortality, cardiogenic shock, acute respiratory distress syndrome, or acute renal injury requiring dialysis or haemofiltration. There was no difference in this composite endpoint between the groups (10% liberal versus 11% restrictive). Independent of transfusion strategy, the number of transfusions correlated with clinical complications and death (hazard ratio 1.2 for each unit transfused).

Based on these trials, a restrictive transfusion threshold (i.e. to maintain the Hb above 8 g/dL or the haematocrit above 24%) appears to be safe in this population.

**EVIDENCE IN HAEMODYNAMICALLY STABLE UPPER GASTROINTESTINAL BLEED**

A single centre trial[16] randomized 921 patients with acute upper gastrointestinal (GI) bleeding to a restrictive or a liberal transfusion strategy (transfusion threshold of 7 g/dL versus vs. 9 g/dL) and determined all-cause mortality at 45 days. Patients with massive bleeding, acute coronary syndrome, history of peripheral vascular disease or stroke, and Hb > 12 g/dL were excluded. All patients underwent emergent upper GI endoscopy within 6 h and were treated with endoscopic therapy as needed. When compared with the liberal transfusion threshold, the restrictive transfusion threshold in these bleeding patients resulted in a lower per cent of patients undergoing transfusion (49% vs. 86%) and fewer transfusions (mean 1.5 vs. 3.7 units) with fewer complications including rebleeding. The mortality from uncontrolled bleeding and also the all-cause mortality were lower in a restrictive group than liberal group.

Therefore a restrictive transfusion strategy may also be extrapolated to patients with bleeding from other sites (e.g. gynaecologic, trauma) who are haemodynamically stable, not at increased risk for complications (e.g. from unstable coronary artery disease) and who have access to rapid surgical intervention.[10]

**EVIDENCE IN PATIENTS WITH TRAUMATIC BRAIN INJURY**

Experimental research studies as well as human observational and physiologic studies have shown that lower Hb concentrations are consistently associated with worse physiologic parameters and clinical outcomes; however, this relationship may not be altered by more aggressive use of RBC transfusions.[17]

A small RCT[18] (n = 67) evaluated restrictive versus a liberal transfusion strategy in patients with moderate to severe closed head injury following multiple trauma. Patients with Hb < 9 were included and randomized to a restrictive RBC transfusion strategy (Hb 7.0 g/dL and maintained between 7.0 and 9.0 g/dL) or a liberal strategy (Hb 10.0 g/dL and maintained between 10.0 and 12.0 g/dL). The 30 days all-cause mortality, presence of multiple organ dysfunction and changes in multiple organ dysfunction from baseline scores were similar between the restrictive and liberal transfusion groups.
SYSTEMATIC REVIEWS AND META-ANALYSIS FOR DIFFERENT TRANSFUSION TRIGGERS

The findings of a Cochrane collaboration meta-analysis (2012)\(^{[19]}\) which included 19 trials with a total of 6264 patients were as follows. Restrictive transfusion strategies reduced the risk of receiving a RBC transfusion by 39% (risk ratio [RR] 0.61, 95% confidence interval [CI] 0.52 to 0.72). The volume of RBCs transfused was reduced on average by 1.19 units (95% CI: 0.53-1.85 units). Restrictive transfusion strategies did not appear to impact the rate of adverse events compared to liberal transfusion strategies (i.e. mortality, cardiac events, MI, stroke, pneumonia and thromboembolism). Restrictive transfusion strategies were associated with a statistically significant reduction in hospital mortality (RR: 0.77, 95% CI: 0.62-0.95) but not 30 days mortality (RR: 0.85, 95% CI: 0.70-1.03). The use of restrictive transfusion strategies did not reduce functional recovery, hospital or ICU length of stay. The majority of patients randomised were included in good-quality trials, but some items of methodological qualities were unclear. There were no trials in patients with acute coronary syndrome.

Thus, this Cochrane meta-analysis\(^{[19]}\) supports the use of restrictive transfusion triggers in most patients, including those with pre-existing cardiovascular disease. As there are no trials, the effect of restrictive transfusion triggers in high-risk groups, such as acute coronary syndrome, needs to be tested in further large clinical trials.

In another meta-analysis,\(^{[20]}\) pooled results from three trials with 2364 participants were included. This meta-analysis showed that a restrictive Hb transfusion trigger of <7 g/dL resulted in reduced in-hospital mortality, total mortality, rebleeding, acute coronary syndrome, pulmonary oedema and bacterial infections compared with a more liberal strategy. Thus, in patients with critical illness or bleed, restricting blood transfusions by using Hb trigger of < 7 g/dL significantly reduces cardiac events, rebleeding, bacterial infections and total mortality.

Thus, overall the evidence supports the notion that restrictive transfusion strategies are at least as good as (and are likely to be better than) liberal transfusion approaches with regards to clinical outcomes of the patients, including those with cardiac conditions excluding acute coronary syndrome. While it seems that liberal RBC transfusions are more likely to cause harm than benefit in the majority of patients, there may be a relatively small group of patients with acute coronary syndrome in whom the benefit of transfusion is likely to outweigh the harm.

TRANSFUSION THRESHOLDS RECOMMENDATIONS

Different societies\(^{[21,22]}\) have published RBC transfusion guidelines. The Hb level chosen in these guidelines are based on the results from clinical trials. It is also important to recognise that lower Hb thresholds have not been tested in most clinical settings and may be tolerated by many patients.

Table 3 illustrates the thresholds for different guidelines.\(^{[22]}\)

SUMMARY OF TRANSFUSION RECOMMENDATIONS

In general, the different guidelines\(^{[3,10,21,22]}\) have the common recommendation that transfusion is not indicated for Hb > 10 g/dL, but the lower threshold varies from 6 to 8 g/dL. The American Association of Blood Banks guideline recommendations\(^{[22]}\) for haemodynamically stable patients without active bleeding are mentioned in Table 4.

This guideline also emphasizes that the decision to transfuse should not be based only on Hb level but should incorporate individual patient characteristics and symptoms.

Clinical judgment is critical in the decision for RBC transfusion above or below the specified Hb threshold and will be directed by clinical situations like duration of anaemia, intravascular volume, extent of the surgery, the probability for massive blood loss and the presence of coexisting conditions such as impaired pulmonary function, inadequate cardiac output, myocardial ischemia, or cerebrovascular or peripheral circulatory disease.\(^{[3]}\)

Assessment of the post-transfusion Hb level can be performed as early as 15 min following transfusion, as long as the patient is not actively bleeding. Major exceptions to the use of a threshold of 7-8 g/dL are given in the Table 5.\(^{[22]}\)

MAXIMUM SURGICAL BLOOD ORDERING SCHEDULE

Introduction

Maximum surgical blood ordering schedule (MSBOS) is a scheduled list of a number of units of blood to
Table 3: Transfusion thresholds for guidelines from different societies

| Target population | CAP 1998 | ASA 2006 | STS 2007 | SCCM 2009 | SIMTI 2011 | AABB 2012 |
|-------------------|----------|----------|----------|-----------|------------|-----------|
| RBC usually indicated (g/dL) | Hb<6 | Hb<6 | Hb<8 (Hb<7 in post-operative with risk of end organ ischaemia) | Hb<7 if ventilated, trauma or stable cardiac disease (Hb<8 if acute coronary syndrome) | Hb<6 (Hb 6-8 if risk factors present; Hb 6-10 if symptoms of hypoxia present) | Hb<7 in critically ill patients; Hbs7 in surgical patients, or patients with pre-existing cardiovascular disease; when symptoms are present |
| RBC rarely indicated (g/dL) | Hb>10 | Hb>10 | Hb>10 | Hb>10 | Hb>10 | Patients with acute coronary syndrome |
| Additional factors to be considered | Peripheral tissue oxygenation, clinical signs and symptoms, extent and rate of bleeding | Ischaemia, extent/rate of bleeding, volume status, risk factors for hypoxia complications | Age, severity of illness, cardiac function, ischaemia, extent/rate of blood loss, SVO2 | Volume status, shock, duration/extent of anaemia, cardio-pulmonary parameters | Rate of blood loss, risk factors, symptoms of hypoxia/ischaemia | Symptoms like chest pain, orthostatic hypotension, unresponsive tachycardia, heart failure |

RBC – Red blood cell; Hb – Haemoglobin; AABB – American Association of Blood Banks; ASA – American Society of Anaesthesiologists; CAP – College of American Pathologists; SCCM – Society of Critical Care Medicine; SIMTI – Italian Society of Transfusion Medicine and Immunohaematology; STS – Society of Thoracic Surgeons; SVO2 – Mixed venous oxygen saturation. Adapted with permission from Shander et al

Table 4: AABB recommendations for RBC transfusion

Hb<6 g/dL – Transfusion recommended except in exceptional circumstances
Hb 6-7 g/dL – Transfusion generally likely to be indicated
Hb 7-8 g/dL – Transfusion should be considered in post-operative surgical patients, including those with stable cardiovascular disease, after evaluating the patient’s clinical status (clinical considerations will include on-going loss)
Hb 8-10 g/dL – Transfusion generally not indicated, but should be considered for some populations (e.g., those with symptomatic anaemia, on-going bleeding, acute coronary syndrome with ischaemia)
Hb>10 g/dL – Transfusion generally not indicated except in exceptional circumstances

AABB – American Association of Blood Banks; RBC – Red blood cell; Hb – Haemoglobin

Table 5: Exceptions to RBC transfusion threshold of 7-8 g/dL

Symptomatic patients may be transfused at higher Hb levels to treat symptoms (symptoms of anaemia requiring transfusion include symptoms of myocardial ischemia, orthostatic hypotension or tachycardia unresponsive to fluid replacement).
Patients with acute coronary syndromes, acute heart failures have not been adequately evaluated in clinical trials and may require higher thresholds for transfusion.
Threshold-based transfusion is not appropriate for patients requiring massive transfusion. In haemodynamically unstable patients transfusion cannot be guided by Hb levels alone and often cannot await interval measurements of Hb.
Transfusion in palliative care patients. Institution specific approaches are different for this indications

RBC – Red blood cell; Hb – Haemoglobin

Steps for implementation of maximum surgical blood ordering schedule

The implementation of MSBOS as explained in the ‘guidelines for implementation of a MSBOS’ – ‘The British Committee for Standards in Haematology Blood Transfusion Task Force’ are simplified into a step-wise approach as below:125

Step-1
Differentiate surgical procedures into those requiring group and antibody screen only and those requiring grouping, antibody screen and cross-matching of blood.

Step-2
Retrospective hospital blood usage data analysis to evaluate the need of group and cross-match for list of commonly performed elective procedures. Cases with complications and exceptional massive transfusions are excluded. Data should be large enough to yield relevant conclusions. Presence of Anaesthesia Information Monitoring Systems with blood usage data will facilitate the collection of information.[26]

Step-3
Evaluate the number of units transfused (T) and the number of units cross-matched (C) for specified elective surgical procedure. C/T ratio, transfusion probability and transfusion index for a specified elective surgical procedure is then determined.

C/T ratio = Number of units cross-matched/number of units transfused.

be cross-matched for different elective surgical procedures. Friedman et al.[24] proposed the concept of MSBOS as early as 1976. With increasing demand for this scarce natural resource, the concept of MSBOS has now been revisited in a number of studies. The advantages of MSBOS are enumerated in the Table 6.
The ideal value of C/T Ratio is 1. Higher values indicate that more number of blood units is cross-matched unnecessarily. However, a realistic C/T ratio of 2–2.5 can be indicative of significant blood usage.

Also, transfusion probability (%T) for a procedure can be determined as the number of patients transfused to number of patients cross-matched.

\[
%T = \frac{\text{Number of patient transfused}}{\text{Number of patients cross-matched}} \times 100
\]

A value of > 30 is considered as indicative of significant blood usage.

Transfusion index for a procedure is defined as the number of units transfused to number of patients cross-matched.

\[
\text{Transfusion index} = \frac{\text{Number of RBC units transfused}}{\text{Number of patients cross-matched}}
\]

**Step-4**

Constructing MSBOS draft schedule using retrospective data. Elective surgical procedures are allotted to the ‘only group and screen’ category or to a ‘group and cross-match’ category.

For some elective surgical procedures such as hysterectomies, caesarean section, hernia repair, transrectal ultrasound-guided biopsy and biopsies, the chances of requiring transfusions are rare. In such cases, only group and antibody screen approach is safe. The advantage of such an approach far outweighs any disadvantage like emergency requirement of blood products that is more often perceived than real.\(^{27}\)

The advantage in terms of blood utilisation and cost has been well-established. It also leads to improved inventory control, which permits enhanced production of blood components and prevents obsolescence of blood.

**Step-5**

Pre-implementation consensus by stakeholders such as surgeons, anaesthesiologist and blood bank is important to ensure ease of implementation. Draft
has to be circulated to surgical and anaesthesia teams. Various factors are to be considered before deciding MSBOS. These include speed and ease of availability of blood products in case of emergency, complexity of procedures and select a group of patients for specified elective procedures.

**Step-6**

Implement the institution specific MSBOS. This includes the following steps:
- Induction of MSBOS
- Preparation of MSBOS cards
- Training of stakeholders.

Monitoring of compliance forms the part of Plan-Do-Study-Act cycle. Computerised blood ordering will help to systematically retrieve procedure-specific data.

**Step-7**

Regular reviews and revisions are done as necessary. MSBOS needs to be regularly updated as there can be changes or refinements in surgical procedures or blood conservation techniques.

Problems with MSBOS: The Table 7 enlists the problems with MSBOS.

Examples of MSBOS recommendations for different procedures and institutions from literature can be referred as a draft while developing institute specific MSBOS algorithm [Table 8]. [28]

**SUMMARY**

Institutional MSBOS algorithm developed with data analysis and consensus of surgeons, anaesthesiologist and blood banks can reduce the over ordering and wastage of blood.

**REFERENCES**

1. Shander A, Javidroozi M, Ozawa S, Hare GM. What is really dangerous: Anaemia or transfusion? Br J Anaesth 2011;107 Suppl 1:i41-59.
2. Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: The search for the elusive transfusion trigger. Vox Sang 2010;98:2-11.
3. Consensus conference. Perioperative red blood cell transfusion. JAMA 1988;260:2700-3.
4. Agency for Healthcare Research and Quality. HCUP Facts and Figures: Statistics on Hospital-Based Care in the United States. Agency for Healthcare Research and Quality; 2007-2010.
5. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weisfeldt LA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683-93.
6. The ARISE Investigators and the ANZICS Clinical Trials Group. Goal-Directed Resuscitation for Patients with Early Septic Shock. N Engl J Med 2014;371:1496-506.
7. Cohen B, Matot I. Aged erythrocytes: A fine wine or sour grapes? Br J Anaesth 2013;111 Suppl 1:i62-70.
8. Blood Transfusion. In Wikipedia, the Free Encyclopedia. Available from: http://www.en.wikipedia.org/w/index.php?title=Blood_transfusion and oldid=629128664. [Last accessed on 2014 Oct 11].
9. Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-507.
10. Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists task force on blood component therapy. Anesthesiology 1996;84:732-47.
11. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarrello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care: A Canadian critical care trials group. N Engl J Med 1999;340:409-17.
12. Holst LB, Haase N, Wetterslev J, Wørneman J, Guttmersen AB, Karlsson S, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371:1381-91.
13. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011;365:2453-62.
14. Bracey AW, Radovancevic R, Rigg SA, Houston S, Cozart H, Vaughn WK, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: Effect on patient outcome. Transfusion 1999;39:1070-7.
15. Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, et al. Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial. JAMA 2010;304:1559-67.
16. Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21.
17. Kramer AH, Zygun DA. Anemia and red blood cell transfusion in neurocritical care. Crit Care 2009;13:R89.
18. McIntyre LA, Fergusson DA, Hutchison JS, Pagliarrello G, Marshall JC, Yetisir E, et al. Effect of a liberal versus restrictive transfusion strategy on mortality in patients with moderate to severe head injury. Neurocrit Care 2006;5:4-9.
19. Carson JL, Carless PA, Hebert PC, Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012;4:CD002042.
20. Salpeter SR, Buckley JS, Chafferjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: A meta-analysis and systematic review. Am J Med 2014;127:124-31.e3.
21. Napolitano LM, Kurek S, Luchette FA, Corwin HL, Barie PS, Fisherman SA, et al. Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care. Crit Care Med 2009;37:3124-37.
22. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, et al. Red blood cell transfusion: A clinical practice guideline from the AABB+. Ann Intern Med 2012;157:49-58.
23. Shander A, Gross I, Hill S, Javidroozi M, Sledge S, College of American Pathologists, et al. A new perspective on best transfusion practices. Blood Transfus 2013;11:193-202.
24. Friedman BA, Oberman HA, Chadwick AR, Kingdon KI. The maximum surgical blood order schedule and surgical blood use in the United States. Transfusion 1976;16:380-7.
25. Guidelines for implementation of a maximum surgical blood order schedule. The British committee for standards in
Iyer and Shah: RBC transfusion strategies and MSBOS

haematology blood transfusion task force. Clin Lab Haematol 1990;12:321-7.

26. Frank SM, Rothschild JA, Masear CG, Rivers RJ, Merritt WT, Savage WJ, et al. Optimizing preoperative blood ordering with data acquired from an anesthesia information management system. Anesthesiology 2013;118:1286-97.

27. Perrault RA, Barr RA. Blood ordering strategies. Prog Transfus Med 1986;1:95-107.

28. Example of a Maximum Surgical Blood Order Schedule Procedure. Available from: http://www.aabb.org/pbm/Documents/msbos.pdf. [Last accessed on 2014 Sep 12].

Source of Support: Nil, Conflict of Interest: None declared

Announcement

**Indian Society of Anaesthesiologists**

**UPDATE YOURSELF – SEND BY EMAIL OR POST TO CITY BRANCH**

1. Name ........................................................................................................................................

2. Father’s Name ...................................................................................................................................

3. Qualification and Year of Passing .............................................................................................

4. ISA. No ........................................................................................................................................

5. Date of Birth .................................................................................................................................

6. Blood Group ..................................................................................................................................

7. Email ID .........................................................................................................................................

8. Year of Membership ....................................................................................................................

9. Address ........................................................................................................................................

10. Town/City .......................................................... State .................................................. Pin code ..........................................

11. Mobile No .................................................................................................................................

12. Passport size photograph- one

13. Signature .....................................................................................................................................

14. City Branch Secretaries’ Seal & Signature................................................................. (Mandatory)

   Note: For city branch details please visit www.isaweb.in

15. State Branch Secretary Seal & Signature................................................................. (Mandatory)

Purpose of Updating: Please tick in the below Box

- Address Change
- Conversion for ALM to LM
- Confirmation as Active Member
- For ID Card
- Fee Rs. 100/- (Payment details are below)

Money to be sent by DD / At par Cheque in favour of “INDIAN SOCIETY OF ANAESTHESIOLOGISTS”) payable at State Bank of India – Secunderabad. OR Online Transfer to A/C No. 30641669810 A/C Name – ISA, State Bank of India, Lalaguda

Dr. M V Bhimeshwar,
Hon. Secretary - ISA (HQ) – isanhq@isaweb.in, Phone: 040 2717 8858, Mobile: +91 98480 40868